Epstein-Barr virus latent membrane protein 1-derived peptide-MHC class I complex (EBV LMP1-pMHC I)

The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1)-derived peptide-MHC class I complex is a critical immunological target for treating EBV-associated malignancies. LMP1 is a primary viral oncogene that mimics CD40 signaling to promote cell survival and proliferation, and it is expressed in various cancers such as nasopharyngeal carcinoma and Hodgkin lymphoma (UniProt P03230). During viral latency, LMP1 is processed into short peptide fragments, such as the HLA-A*02:01-restricted epitope YLLEMLWRL, which are then presented on the cell surface by MHC class I molecules (PubMed: 15141005). These complexes are recognized by the T-cell receptors (TCRs) of cytotoxic T lymphocytes, making them ideal targets for adoptive T-cell therapies and TCR-like antibodies (PubMed: 31533914). Because LMP1 is a viral protein, these pMHC complexes provide a high degree of tumor specificity compared to many self-antigen targets. However, therapeutic efficacy can be challenged by the downregulation of MHC molecules by tumor cells or the potential for cross-reactivity with similar human peptide sequences. Current clinical strategies include the use of EBV-specific cytotoxic T lymphocytes and engineered TCR-T cell therapies designed to recognize these specific peptide-HLA combinations.

Other names

LMP1 peptide-HLA complexEBV LMP1 epitope-MHC ILMP1-pMHCEpstein-Barr virus latent membrane protein 1-derived peptide-HLA complexYLLEMLWRL-HLA-A*02:01 complex

T-cell receptor (TCR) mediated cell lysis; Antibody-dependent cellular cytotoxicity (ADCC); T-cell activation and proliferation